Lipid/Lipoprotein Structure and Metabolism (Overview)
|
|
- Rosalind Lloyd
- 6 years ago
- Views:
Transcription
1 Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia
2 Disclosures Received honorariums for participating as a consultant or as a member of advisory boards for AMGEN, AstraZeneca, CSL-Behring, Lilly, Merck, Novartis, Pfizer and Roche and for giving lectures for AMGEN, AstraZeneca, Merck and Pfizer.
3 Atherosclerotic Cardiovascular disease
4 Atherosclerotic Cardiovascular disease
5 Clinical manifestations of Atherosclerotic Cardiovascular Disease (ASCVD) Coronary artery: Myocardial infarction Carotid artery: Stroke Mesenteric artery: Intestinal gangrene Other arteries: Peripheral arterial disease
6 Modifiable Risk Factors for Atherosclerotic Cardiovascular disease (ASCVD) Smoking Elevated low density lipoproteins (LDLs) Elevated triglyceride-rich lipoproteins Reduced high density lipoproteins (HDLs) Elevated blood pressure Diabetes Abdominal obesity
7 Modifiable Risk Factors for Atherosclerotic Cardiovascular disease (ASCVD) Smoking Elevated low density lipoproteins (LDLs) Elevated triglyceride-rich lipoproteins Reduced high density lipoproteins (HDLs) Elevated blood pressure Diabetes Abdominal obesity
8 Plasma lipoproteins Why do we have plasma lipoproteins? What are plasma lipoproteins? What is the metabolism of plasma lipoproteins? What is the relationship of plasma lipoproteins to atherosclerosis?
9 Plasma lipoproteins Why do we have plasma lipoproteins? What are plasma lipoproteins? What is the metabolism of plasma lipoproteins? What is the relationship of plasma lipoproteins to atherosclerosis?
10 Why do we have plasma lipoproteins? Main reason for having plasma lipoproteins is to transport triglyceride and cholesterol through plasma between tissues Plasma is mainly water and cholesterol and triglyceride are not water-soluble Incorporation of cholesterol and triglyceride into lipoproteins allows them to be transported in plasma
11 Why do we have plasma lipoproteins? Several other functions of plasma lipoproteins will be covered in other lectures
12 Plasma lipoproteins Why do we have plasma lipoproteins? What are plasma lipoproteins? What is the metabolism of plasma lipoproteins? What is the relationship of plasma lipoproteins to atherosclerosis?
13 Structure of plasma lipoproteins Surface monolayer of phospholipids and free cholesterol apolipoproteins Hydrophobic core of triglyceride and cholesteryl esters
14 Lipoprotein fractions in plasma Chylomicrons, VLDLs, and their catabolic remnants Pro-atherogenic LDLs HDLs Anti-atherogenic
15 Chylomicrons Formed in intestinal cells Function to transport dietary triglyceride and cholesterol to tissues in the body Main core lipid is triglyceride Main protein is apob-48
16 Very low density lipoproteins (VLDLs) Formed in the liver Function to transport triglyceride and cholesterol from the liver to tissues in the body Main core lipids is triglycerides Main protein is apob-100
17 Low density lipoproteins (LDLs) Formed as end-products of the catabolism of VLDLs Function to transport cholesterol from plasma to tissues in the body Main core lipids are cholesteryl esters Main protein is apob-100
18 High density lipoproteins (HDLs) Assembled within the plasma from several constituents Function to transport intracellular cholesterol into the plasma Main core lipids are cholesteryl esters Main proteins are apoa-i and apoa-ii
19 Plasma lipoproteins Why do we have plasma lipoproteins? What are plasma lipoproteins? What is the metabolism of plasma lipoproteins? What is the relationship of plasma lipoproteins to atherosclerosis?
20 Plasma lipid transport: Exogenous pathway
21 Formation of chylomicrons Chylomicron Lymph (thoracic duct) Blood FC FFA Intestinal cell Free cholesterol (FC) Free fatty acid (FFA) Intestinal lumen
22 Metabolism of chylomicrons Intestine Chylomicron LPL FFA Adipose and other tissues TP Liver HDL Chylomicron remnant
23 Plasma lipid transport: Endogenous pathway
24 Endogenous pathway Liver FC FFA Adipose tissue
25 Endogenous pathway FC Liver VLDL FFA Adipose tissue
26 Endogenous pathway Liver VLDL FC LPL FFA FFA Adipose and other tissues Adipose tissue
27 Endogenous pathway Liver VLDL FC LPL FFA FFA LDL Adipose and other tissues Adipose tissue
28 Endogenous pathway Liver VLDL FC LPL FFA FFA LDL Adipose and other tissues Adipose tissue Liver LDL receptor
29 Endogenous pathway Liver VLDL FC LPL FFA FFA LDL Adipose and other tissues Adipose tissue Liver LDL receptor LDL receptor Cell in peripheral tissue
30 Endogenous pathway Liver VLDL FC LPL FFA FFA LDL Adipose and other tissues Adipose tissue Liver LDL receptor LDL receptor FC New synthesis Cell in peripheral tissue
31 Endogenous pathway Liver VLDL FC LPL FFA FFA LDL Adipose and other tissues Adipose tissue Liver LDL receptor LDL receptor HDL LCAT ABCA1 FC New synthesis Cell in peripheral tissue
32 Endogenous pathway Liver VLDL FC FFA LPL LDL FFA Adipose and other tissues Adipose tissue Liver LDL receptor LDL receptor HDL LCAT ABCA1 FC New synthesis Cell in peripheral tissue
33 Endogenous pathway Liver VLDL FC FC FFA LPL LDL FFA Adipose and other tissues Adipose tissue Liver LDL receptor LDL receptor Bile HDL LCAT ABCA1 FC New synthesis Cell in peripheral tissue
34 Endogenous pathway Liver VLDL FC FC FFA LPL LDL FFA Adipose and other tissues Adipose tissue TP Liver LDL receptor LDL receptor Bile HDL LCAT ABCA1 FC New synthesis Cell in peripheral tissue
35 Formation and metabolism of HDL
36 Structure of HDL Surface monolayer of phospholipids and free cholesterol apoa-i apoa-ii Hydrophobic core of triglyceride and cholesteryl esters
37 HDL Charge and shape Lipid-poor apoa-i Prebeta mobility Discoidal Prebeta mobility Spherical Alpha mobility
38 HDL Subpopulations PARTICLE SHAPE APOLIPOPROTEIN COMPOSITION Discoidal Spherical A-I HDL A-I/A-II HDL PARTICLE SIZE Lipid-poor apoa-i HDL 2b HDL 2a HDL 3a HDL 3b HDL 3c
39 Formation of HDL LIVER INTESTINE Chylomicrons Lipid-poor apoa-i Lipolysis
40 Lipidation of apoa-i to form discoidal HDL Lipid-poor apoa-i Cell membrane ABCA-1 phospholipid, cholesterol Discoidal HDL
41 Role of LCAT in formation of spherical HDL Liver Intestine Free cholesterol transferred from cell membranes (including liver and intestine) apoa-i free cholesterol LCAT cholesteryl esters Discoidal HDL Spherical HDL
42 Role of TP and SRB1 in HDL metabolism Liver LDL-R SR-B1 FC SR-B1 TP VLDL/LDL Bile HDL LCAT FC Extrahepatic Tissues (including the artery wall Free Cholesterol
43 Plasma lipoproteins Why do we have plasma lipoproteins? What are plasma lipoproteins? What is the metabolism of plasma lipoproteins? What is the relationship of plasma lipoproteins to atherosclerosis?
44 ATHEROSCLEROSIS
45 ATHEROSCLEROSIS Monocyte Vessel Lumen Adhesion Molecule MCP-1 Endothelium Intima Macrophage Foam Cell
46 Lipoprotein classes and atherosclerosis Non-HDL Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic
47 ROLE OF LDLs IN CAUSING ATHEROSCLEROSIS Monocyte LDL Vessel Lumen Adhesion Molecule MCP-1 LDL Endothelium Cytokines MODIFIED LDL Intima Macrophage Foam Cell
48 It has been proven beyond all doubt in many large clinical trials that reducing level of LDL cholesterol reduces the risk of having a cardiovascular event
49 CLINICAL INTERVENTION TRIALS REDUCTION IN MCVEs EVENTS (%) SEARCH IMPROVE-IT ALLHAT IDEAL LRC LIPID CARE TNT HPS AFCAPS Posch ASCOT WOS 4S CARDS JUPITER REDUCTION IN LDL CHOLESTEROL (mg/dl)
50 Lipoprotein classes and atherosclerosis Non-HDL Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic
51 ROLE OF TRIGLYRIDE-RICH LIPOPROTEINS (TRLS) IN CAUSING ATHEROSCLEROSIS Monocyte TRL remnants Vessel Lumen Adhesion Molecule MCP-1 TRL remnants Endothelium Cytokines Modified TRL remnants Intima Macrophage Foam Cell
52 It is likely (but still not proven) that reducing levels of triglyceride-rich lipoproteins will reduce the risk of having a cardiovascular event
53 INHIBITION OF ATHEROSCLEROSIS BY HDLs Monocyte HDL INHIBIT ADHESION MOLECULE EXPRESSION HDL INHIBIT MCP-1 EXPRESSION LDL Vessel Lumen Adhesion Molecule MCP-1 LDL Endothelium HDL INHIBIT OXIDATION OF LDL Cytokines MODIFIED LDL Intima Macrophage HDL PROMOTE CHOLESTEROL EFFLUX Foam Cell
54 It is possible (but not proven) that increasing levels of HDLs will reduce the risk of having a cardiovascular event
55 Conclusions Plasma lipoproteins transport triglyceride and cholesterol through plasma between tissues LDLs and the remnants of triglyceride-rich lipoproteins cause atherosclerosis, while HDLs protect Reducing plasma levels of LDL cholesterol reduces the risk of having a cardiovascular event It is still not known whether decreasing triglyceride-rich lipoproteins or increasing HDL levels reduce cardiovascular risk
High density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationLipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationLipids digestion and absorption, Biochemistry II
Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More informationPlasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam
Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationCholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies
More informationAcetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationCholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia
Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationLipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels
Lipoprotein Formation, Structure and Metabolism: Balance and the Regulation of Plasma Lipid Levels David E. Cohen, MD, PhD Director of Hepatology, Gastroenterology Division, Brigham and Women s Hospital
More informationPPAR history of research
PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,
More informationCholesterol Metabolism
Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000
More informationPLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL
PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationRegulating Hepatic Cellular Cholesterol
Under circumstances of cholesterol deficiency, Sterol Regulatory Element Binding Proteins (SREBPs) via binding to DNA nuclear response elements set off genomic production of proteins and enzymes that induce
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More information5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT
5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT Prof. Victor Blaton, Ph.D. Department of Clinical Chemistry, Hospital AZ Sint-Jan
More informationCHM333 LECTURE 34: 11/30 12/2/09 FALL 2009 Professor Christine Hrycyna
Lipid Metabolism β-oxidation FA Acetyl-CoA Triacylglycerols (TAGs) and glycogen are the two major forms of stored energy in vertebrates Glycogen can supply ATP for muscle contraction for less than an hour
More informationTopic 11. Coronary Artery Disease
Topic 11 Coronary Artery Disease Lipid metabolism http://news.bbc.co.uk/2/hi/health/7372495.stm Sterol Metabolism and Coronary Artery Disease Big Picture: Exogenous Cholesterol and Fat Metabolism Fats-Triglycerides
More informationMoh Tarek + Suhayb. Tamara Al-Azzeh + Asmaa Aljeelani ... Faisal
28 Moh Tarek + Suhayb Tamara Al-Azzeh + Asmaa Aljeelani... Faisal Digestion of dietary lipids Lipid digestion and absorption are complex processes. They involve soluble enzymes, substrates with different
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationCHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL
CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL You will notice that the endogenous pathway is very similar to the exogenous pathway What is the average daily amount of triacylglycerol
More informationHDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society
ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationThe Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C
The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationCholesterol and its transport. Alice Skoumalová
Cholesterol and its transport Alice Skoumalová 27 carbons Cholesterol - structure Cholesterol importance A stabilizing component of cell membranes A precursor of bile salts A precursor of steroid hormones
More informationLIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE
LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE Sebastiano Calandra Dipartimento di Scienze Biomediche Università di Modena e Reggio Emilia Incidence Rate/1000 200-150 - 100-50 - Women 0 Men
More informationNiacin Metabolism: Effects on Cholesterol
Niacin Metabolism: Effects on Cholesterol By Julianne R. Edwards For Dr. William R. Proulx, PhD, RD Associate Professor of Nutrition and Dietetics In partial fulfillments for the requirements of NUTR342
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationCellular control of cholesterol. Peter Takizawa Department of Cell Biology
Cellular control of cholesterol Peter Takizawa Department of Cell Biology Brief overview of cholesterol s biological role Regulation of cholesterol synthesis Dietary and cellular uptake of cholesterol
More informationLipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel
Lipid Metabolism Department of Biochemistry and Molecular Biology II Medical Center Hamburg-ppendorf 1 Lipids. visceral fat. nutritional lipids 0 1.5 3 4.5 9 h. serum lipids. lipid accumulation in the
More informationContributions in Medicine: Will CETP Inhibition Contribute Toward Reduction of Cardiovascular Risk?
Contributions in Medicine: Will TP Inhibition Contribute Toward Reduction of Cardiovascular Risk? Activity presentations are considered intellectual property. These slides may not be published or posted
More informationA Study of Omega-3 Fatty Acid. Therapy in Patients with. Nephrotic Syndrome
A Study of Omega-3 Fatty Acid Therapy in Patients with Nephrotic Syndrome Dr Samira Siddiqui Renal Unit Glasgow Royal Infirmary Thesis for the degree of MD, Faculty of Medicine, University of Glasgow Submitted
More informationThe role of HDL-cholesterol in preventing atherosclerotic disease
European Heart Journal Supplements (2005) 7 (Supplement F), F4 F8 doi:10.1093/eurheartj/sui036 The role of HDL-cholesterol in preventing atherosclerotic disease Philip Barter* The Heart Research Institute,
More informationNutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source
Tools: Printer 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut along dashed lines Copyright Goodheart-Willcox Co., Inc. All rights reserved. Tissue in which the body
More informationLIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI
LIPID METABOLISM Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI Lipid metabolism is concerned mainly with fatty acids cholesterol Source of fatty acids from dietary fat de novo
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationNutrition, Food, and Fitness. Chapter 6 Fats: A Concentrated Energy Source
Nutrition, Food, and Fitness Chapter 6 Fats: A Concentrated Energy Source Tools: Printer (color optional) 4 sheets of 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationMETABOLISM of ADIPOSE TISSUE
METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationHealth and Disease of the Cardiovascular system
1 Health and Disease of the Cardiovascular system DR CHRIS MOORE Instructions 2 USE THE ARROWS TO NAVIGATE, OR TAP OUTLINE AT THE TOP TO BRING DOWN A SLIDE MENU Click these where you see them to zoom or
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationCholesterol, Heart Attack and Stroke. Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital
Cholesterol, Heart Attack and Stroke Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital Outline Why are we interested in cholesterol What is a heart attack and how does it
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationTabac et Lipides. Michel FARNIER, MD, PhD, Dijon
Tabac et Lipides Michel FARNIER, MD, PhD, Dijon Dr Farnier reports having received grants, consulting fees and/or honoraria and delivering lectures for Abbott, Akcea/Ionis, Amarin, Amgen, AstraZeneca,
More informationBlood fatty acids understanding the relevance of different tissue fractions and interpreting circulating concentrations.
Blood fatty acids understanding the relevance of different tissue fractions and interpreting circulating concentrations Leanne Hodson Fatty acid composition as a biomarker of intake Complements dietary
More informationIntroduction REVIEW. M. John Chapman*, Wilfried Le Goff, Maryse Guerin, and Anatol Kontush. Keywords
European Heart Journal (2010) 31, 149 164 doi:10.1093/eurheartj/ehp399 REVIEW Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin,
More informationSTRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty
STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE OF LIPIDS AND LIPOPROTEINS DEFINTITION: Compounds Insoluble in water But
More informationDysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE
Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE PIs and Members of HDL Project Wei Gao, M.D., Ph.D. Professor and Chair Cardiology Third Hospital, PUHSC Yong Huo, M.D., Ph.D.
More informationIncorporating HDL interaction in an ODE model of Atherosclerosis
Incorporating HDL interaction in an ODE model of Atherosclerosis Diego Lopez Texas A&M University July 29, 2015 Diego Lopez (TAMU) July 29, 2015 1 / 10 Introduction Atherosclerosis A disease of the arteries
More informationSupplemental Material. Results
Supplemental Material Results Fractionation of mouse plasma by high-resolution SEC. APOA1 eluted as a single major peak in fractions 16 of plasma (the apparent size of mature, lipidated HDL) when it was
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Shlomo Eieenberg Lipid Research Laboratory, Department of Medicine B, Hadassah University Hospital, Jerusalem, Israel 1. INTRODUCTION Interest in high density lipoproteins
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More information10/1/2008. Therapy? Disclosure Statement
What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationGeneral pathophysiology LIPID METABOLISM
General pathophysiology LIPID METABOLISM 1. Alimentary chylomicronemia is sustained in: 1. Lipoprotein lipase deficiency. 2. Inhibited lipoprotein lipase. 3. Hypoalbuminemia. 4. Hyperalbuminemia. 2. Direct
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationDigestion and transport of TAG by plasma lipoproteins
Digestion and transport of TAG by plasma lipoproteins Lipoproteins are multimolecular complexes of lipids and proteins, they are not macromolecules They transport lipids in the plasma because lipids are
More informationInspired Functional Ingredients to Innovate and Differentiate Your Brand. Products by Ecovatec Solutions Inc.
Inspired Functional Ingredients to Innovate and Differentiate Your Brand Products by Ecovatec Solutions Inc. High Density Lipopeptides (HDL p ) High Density Lipopeptides (HDL p ) High density lipoproteins
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationCHAPTER 1. General Introduction
CHAPTER 1 General Introduction General Introduction Contents 1. Lipoproteins and lipid metabolism 1. Exogenous pathway 2. Endogenous pathway 3. Reverse cholesterol pathway 2. Atherosclerosis 1. Pathogenesis
More informationAIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)
AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,
More informationDr Jeremy Sayer Consultant Cardiologist St. Bartholomew s Hospital
Your Heart Would you get Standard Rates? Dr Jeremy Sayer Consultant Cardiologist St. Bartholomew s Hospital Freitag, 28. Mai 2010 Page 1 Summary Cardiovascular Risk Estimation of cardiovascular risk Further
More information